What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Ghrelin / GHSR pathway GH-release peptide
PeptideXpo buyer fit
This PeptideXpo page is intentionally positioned for distributors, OEM buyers, and procurement teams comparing Ipamorelin inside a wider peptide catalog. It is not trying to be the deepest single-molecule monograph; the differentiated intent is assortment planning, export-ready documentation, fill-size comparison, and whether this SKU belongs in a broader buyer program.
Overview
Ipamorelin is a synthetic 5-amino-acid pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) engineered as a highly selective GHSR (ghrelin / growth-hormone secretagogue receptor) agonist. Unlike the broader GHRP family (GHRP-2, GHRP-6, Hexarelin), Ipamorelin's selectivity for GHSR over the related receptors that regulate cortisol, prolactin, and ACTH release makes it the most clean GH-selective GHSR agonist in routine research use, the absence of cortisol-axis activation is the defining pharmacological feature relative to the older GHRP analogues. PeptideXpo supplies Ipamorelin acetate as a lyophilized powder at ≥99.0% HPLC purity. The short sequence makes synthesis straightforward, and the analytical packet emphasizes peak-integration HPLC plus mass spec, sequence verification by LC-MS/MS is available on request but is rarely the critical test for a 5-residue peptide. Ipamorelin is most commonly combined with a GHRH-pathway agonist (CJC-1295 no-DAC, Sermorelin, or Tesamorelin) in dual-pathway research and compounding workflows; the canonical CJC-1295 + Ipamorelin blend is supplied pre-co-lyophilized under the cjc-1295-ipamorelin SKU at standard 5+5 mg ratios with custom ratios via OEM service. For the full pharmacology of the dual-pathway approach, see our [CJC-1295 + Ipamorelin guide](/insights/cjc-1295-ipamorelin-blend-pharmacology-guide).
Who buys this, and why
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want bulk lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.
Specifications
Documentation available on request
Regulatory note
Sold as a bulk active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
Frequently asked questions
All three are GHSR (ghrelin receptor) agonists, but they differ in their selectivity profile. GHRP-2 and GHRP-6 also activate the receptors involved in cortisol release, prolactin secretion, and (for GHRP-6 especially) appetite stimulation, these off-target effects can confound research readouts and are clinically undesirable in compounding-pharmacy applications. Ipamorelin's pentapeptide design was specifically engineered to retain the GHSR-binding affinity while losing the cortisol-pathway activation, making it the cleanest GHSR-selective agonist in routine use. The trade-off is that GHRP-2 and GHRP-6 produce somewhat larger GH-release magnitudes; Ipamorelin produces a more selective but slightly smaller GH pulse.
Ipamorelin acts on the GHSR; CJC-1295 acts on the GHRH receptor. These are two parallel pathways converging on the same somatotroph cells, and combining a GHSR-pathway agonist with a GHRH-pathway agonist produces GH-release magnitudes substantially larger than either component alone at comparable individual doses. The standard combination ratio is 1:1 by mass (typically 5+5 mg per vial). For research workflows studying GHSR pharmacology in isolation, Ipamorelin alone is the appropriate choice; for GH-release-maximizing workflows, the dual-pathway combination is essentially universal.
Ipamorelin reconstitutes cleanly in bacteriostatic water for injection at typical research concentrations (1-5 mg/mL is common). The reconstituted solution is reasonably stable at -20 °C as single-use aliquots, but as with the rest of the GH-axis class, freeze-thaw cycling is the dominant source of measured-potency loss. The operational guidance is to split into the smallest workable aliquot volumes immediately after reconstitution and limit thaw cycles to three or fewer. The lyophilized product itself follows the standard 24-month re-test window at -20 °C.
Related peptides
Modified GRF 1-29 · GHRH analog
29-mer
GHRH 1-29 fragment
GH-axis blend (CJC-1295 no DAC + Ipamorelin)
